Evidence map›Paper›PMID 38982546›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2024

Baseline and early

Charline Lasnon, Adeline Morel, Nicolas Aide, Angélique Da Silva, George Emile

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Prognostic value of TMTV and Dmax calculated fromEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charline LasnonNuclear Medicine Department, François Baclesse Comprehensive Cancer Center, UNICANCER, 3 Avenue du General Harris, BP 45026, Caen Cedex 5, 14076, France. c.lasnon@baclesse.unicancer.fr.ORCID http://orcid.org/0000-0001-5643-1668
Adeline MorelMedical Oncology Department, François Baclesse Comprehensive Cancer Center, UNICANCER, Caen, France.
Nicolas AideUNICAEN, INSERM 1086 ANTICIPE, Normandy University, Caen, France.
Angélique Da SilvaMedical Oncology Department, François Baclesse Comprehensive Cancer Center, UNICANCER, Caen, France.
George EmileMedical Oncology Department, François Baclesse Comprehensive Cancer Center, UNICANCER, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExploring the value of baseline and early

methodsSixty-six consecutive breast cancer patients who underwent a pre-therapeutic

resultsThe median follow-up was equal to 22.5 months. Thirty progressions occurred (45.4%). The average time to event was 17.8 ± 10.4 months. At baseline, D

conclusionDisease spread at baseline PET, as assessed by D

Indexed as

Breast NeoplasmsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedCyclin-Dependent KinasesFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisProgression-Free SurvivalProtein Kinase InhibitorsRetrospective StudiesCyclin-Dependent KinasesFluorodeoxyglucose F18Protein Kinase InhibitorsRadiopharmaceuticalsBreast cancerCyclin-dependent kinase inhibitorFDGPETTargeted therapy

Identifiers

PMID38982546
PMCPMC11232230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.